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ABSTRACT 
Cancer is currently one of the leading causes of mortality and morbidity worldwide. 
Most anticancer therapies rely on small molecule drugs (<0.5 kDa). As with all small 
molecule drugs, chemotherapy is highly toxic and presents many off-target side 
effects. Peptide drugs offer improved specificity and are cheaper and more accessible 
to manufacture. In this study, we have developed a support vector machine (SVM) 
model in order to detect peptide sequences with potential anticancer activity through 
scanning the Red Sea Metagenomic library. Furthermore, we conducted an in silico 
study in order to analyze one of the peptides returned by the SVM pipeline and 
assessed its cytotoxicity and the mode of cell death by conducting MTT and Annexin 
V staining assays, respectively. We observed that the selected anticancer peptide 
contains the C-terminal portion of the homeodomain structure, of human Pax6, an 
antennapedia homeodomain region, and can bind DNA. Furthermore, we observed 
dose-response cytotoxicity of HepG2 cells with our peptide. No such cytotoxicity 
was observed in HeLa cells; a morphological change, however, was observed. We 
examined the cytotoxicity of our drug against 1BR-hTERT normal skin cells. Our 
peptide drug induced dose-dependent cytotoxicity that was markedly weaker than 
that of cancer treated cells. Together our data illustrates the isolation of one peptide 
drug candidate from the AUC Red Sea metagenomic library; furthermore, we were 
able to observe the selective dose-dependent reduction of HepG2 cell viability
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INTRODUCTION 
1 )  L i t e r a t u r e  R e v i e w  
Cancer is currently one of the leading causes of mortality and morbidity 
worldwide. In 2012, about 8 million deaths occurred around the world due to cancer, 
and about 14 million new cases appeared; the number of new cancer cases per year 
has been expected to rise by about 70% over the next two decades [1]. Cancer is a 
term given to a collection of diseases characterized by uncontrolled cell division. The 
abnormal tumor cells, which arise from normal cells, are able to grow anywhere in 
the body and can arise from any tissue or cell type. As opposed to benign tumors, 
malignant tumors (also known as cancers) can spread throughout the body and invade 
any type of tissue far from the site of the original tumor. The cancer cells use blood 
vessels and lymph vessels to travel around the body. In contrast to normal cells, 
cancer cells are undifferentiated; that is, they may not carry out the same specific 
functions as the original normal tissue cells. Moreover, cancer cells are desensitized 
to the external chemical signals that regulate their growth, division, and functions. 
Cancer cells are also able to influence their microenvironment; for example, a cancer 
mass can influence the development of blood vessels, a process known as 
angiogenesis, in order to provide itself with nutrients and waste removal. One of the 
functions of the immune system is removal of the body’s aging and/or aberrant cells; 
cancer cells however, have evolved mechanisms by which they can evade removal 
by the immune system. Cancer arises through genetic changes in the normal cell (the 
process of carcinogenesis); those changes can fall within one or a combination of 
three main classes of genes: proto-oncogenes, tumor suppressors, or DNA repair 
genes. Proto-oncogenes and tumor suppressor genes are responsible for ensuring 
normal cell development, growth, and division while DNA repair genes are 
specialized in repairing any mutations that can arise in the cell’s DNA. Mutations to 
proto-oncogenes and tumor suppressors may occur due to exposure to mutagenic 
agents such as radiation; failure to repair these mutations by the DNA repair 
machinery results in the persistence of these mutations and subsequently results in 
carcinogenesis. As is the case with the other genes, mutations to the DNA repair 
genes can also develop through environmental stimuli or through aging [2, 3]. 
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The currently used regiments for treating cancer remain problematic. The 
foremost problem with conventional chemotherapy is the failure to administer the 
correct amount of the chemotherapeutic agent directly and selectively to the tumor 
mass or tissue. As a result, the treatment itself may become toxic to the patient. 
Furthermore, several drug resistance mechanisms have been reported. Once the 
chemotherapeutic agents have been transported into the cell, intracellular transport 
mechanisms may re-route the chemotherapeutic agents back out of the cell before 
they could interact with their intracellular targets. Clearly, there is a need for more 
selective, more potent, and less toxic cancer therapeutics [4-6]. 
Towards the latter part of the 20th century, new classes of cancer therapeutics have 
come into existence (namely, protein-based therapeutics) due to the advancements in 
biotechnological techniques of that time (such as recombinant protein expression and 
enhanced protein purification and analysis protocols). These new protein-based 
therapeutics, or “biologics”, offer several advantages over the “small-molecule” 
drugs: very high selectivity towards their targets, fewer side effects, and subsequently 
higher potency. Examples of currently used biologics therapeutics include insulin, 
growth factors, and engineered antibodies [6]. Biologics, however are tedious and 
expensive to manufacture [6].  
Small peptide drugs combine the best of both worlds: they possess the hallmark 
potency and specificity of biologics, but are much smaller in size, more accessible, 
and much cheaper to manufacture [6]. 
Among the classes of peptide drugs, are anticancer peptides [6]. Anticancer 
peptides are small (5 to 50 amino acids), cationic, amphiphilic peptides [4-6]. The 
major feature of anticancer peptides that dictates their specificity towards cancer cells 
is their cationic net charge. In contrast to the normal cells, cancer cells have a 
relatively negative charge; this relative negative charge is a result of the over-
expression of anionic cell surface molecules such as phosphatidylserine, O-
glycosylated mucins, siasilated ganglioside, and heparan sulfates [5, 7]. The 
anticancer peptides are therefore, attracted to the membrane of cancer cells merely 
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through simple electrostatic interactions. However, membrane fluidity and 
cholesterol content also affect the accessibility of the peptide into the cell [8]. 
Two main modes of action have been described for anticancer peptides: 
membranolytic and non-membranolytic (Figure 1). Anticancer peptides acting 
through the membranolytic mechanisms disrupt either the cell membrane, 
mitochondrial membrane, or lysosomal membrane. The anticancer peptides can 
disrupt the plasma membrane by either the carpet or barrel stave models. In the carpet 
model, the cationic anticancer peptides align parallel to the cell membrane, and once 
Figure 1: 3D representation of the major modes of action described for known 
anticancer peptides so far. Mechanisms of action fall broadly into 2 categories: 
Those which are membranolytic (left half-cell) and those which are non-
membranolytic (right half- cell). The membranolytic modes of action affect the 
membranes of the cell, lysosome, or mitochondria (1, 2, 3, respectively). The non-
membranolytic modes of action either modify gene expression of pro-survival genes 
and induce cell cycle arrest, or affect activity of calcium ion channels and proteasome 
(4, 5, 6). 
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a certain threshold concentration of the peptide is reached, the peptides can permeate 
the plasma membrane. In contrast, anticancer peptides can aggregate, by hydrophobic 
interactions, to form a structure through the plasma membrane resembling a 
traditional ion channel. Anticancer peptides can also pass through the plasma 
membrane and permeate the mitochondrial membrane where they will induce 
swelling of the mitochondria and release of cytochrome c. Release of cytochrome c 
can subsequently activate caspase 9 and 3. Furthermore, modification of the 
lysosomal membrane by anticancer peptides can result in acidification of the cytosol. 
The non-membranolytic mechanisms of action include activation of calcium 
channels resulting in calcium ion influx, augmentation of proteasome activity, 
inhibition of pro-survival genes, or cell cycle arrest [5, 9].  
The HPRP-A2 peptide, described by Zhao et. Al. [10], has been found to rapidly 
induce cytotoxicity in two gastric cancer cell lines by means of cellular membrane 
destruction (Table 1). They described a combined mechanism by which the HPRP-
A2 peptide induces a rise in the intracellular levels of reactive oxygen species and the 
depolarization of the mitochondrial membrane, which is indicative of mitochondrial 
damage. The peptide was also able to result in cell cycle arrest. Furthermore, the 
HPRP-A2 peptide resulted in increased cytotoxicity when used in combination with 
chemotherapy. In contrast, the Kahalides can trigger modification of the lysosomal 
membrane which results in cell death [9, 11]. The Kahalides come from an alga, 
Bryopsis, that the saltwater marine mollusk, Elysia rufescens feeds on; Kahalide has 
undergone phase II clinical trials against solid tumors [12]. Melittin is another 
anticancer peptide; it has been described to induce apoptosis in HepG2 cells by 
calcium ion influx through the activation of Ca2+/Calmodulin dependent protein 
kinase [13]. Other peptides have been described to act in a combination of different 
modes of action encompassing, in some cases such as Magainin, most of the known 
mechanisms [9]. 
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Table 1: Mode of action of some representative anti-cancer peptides. 
2 )  O b j e c t i v e s  
In this study, we attempt to construct a support vector machine (SVM) pipeline 
that can detect peptide sequences with potential anticancer activity. We also select 
the best candidate from the list of potential anticancer peptides and attempt to further 
examine its potential anticancer activity through protein structure prediction, 
modelling, visualization, and ligand binding prediction. We Also provide in vitro 
evidence of the anticancer effect of our peptide.
Peptide name Mechanism of action Publication 
HPRP-A2 
Cell membrane 
desaturation 
Mitochondrial 
membrane destruction 
Cell cycle arrest 
Zhao et. Al., 2015 
Kahalide Lysosomal membrane modification Hamann and Otto, 1996 
Melittin Calcium ion influx Wang et. Al., 2009 
Magainin 
Mainly membrane 
destruction 
Other modes of action 
described 
Mulder et. Al. 2013 
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MATERIALS AND METHODS 
1 )  C o m p u t a t i o n a l  M o d e l i n g  
A. METAGENOMIC LIBRARY SCREENING AND CANDIDATE 
PEPTIDE SELECTION 
We adapted the method proposed by Tyagi et. Al. 2013 [14]  for mining large 
datasets containing potential anticancer peptide sequences in order to search the AUC 
Metagenomic library. We compared a dataset of experimentally validated anticancer 
peptides [15-19] to a dataset of antimicrobial peptides and another dataset of random 
peptides. 
All possible oligopeptide frequencies were investigated in a size range of 1 to 30 
amino acids. We also calculated the amino acid and dipeptide (2 amino acids) 
frequencies for the anticancer and antimicrobial datasets. We compared the 
frequencies of amino acids and dipeptides in the anticancer and antimicrobial peptide 
datasets to those of the peptides in the Metagenomic library (t-test, P<0.05, 
Bonferroni multiple testing correction). Only the peptides recognized as anticancer 
were chosen. A sliding window of increasing size, starting from 5 amino acids, was 
used to generate the peptides from the Metagenomic library translated reads. The 
recognized peptides were scored according to how well they conform to the mean 
amino acid and dipeptide frequencies of the experimentally proven anticancer 
dataset, that is, they fall within the standard error from the mean. 
We searched the passing peptides for presence of Hidden Markov Models 
(HMM’s) [20, 21] previously reported on experimentally verified anticancer 
peptides. 
We confirmed our final predictions using the online tool developed by Tyagi et al 
[14] (http://crdd.osdd.net/raghava/anticp/). 
B. FILTERING A SINGLE CANDIDATE FOR MODELLING 
We selected a single anticancer peptide from the final shortlist of potential 
anticancer peptides for modelling. The criteria used were cationicity, model 
prediction score, and size. 
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C. PEPTIDE PERFORMANCE OPTIMIZATION 
In order to increase the statistical performance of our peptide, when run against a 
dataset of experimentally validated and random peptides, we carried out a series of 
optimization steps. We ran the peptide sequence as a FASTA file on the AntiCP web 
server for anticancer peptide prediction. We chose model 2 for analysis, which 
compares the query to a set of experimentally validated anticancer peptides and 
random peptides, as opposed to a dataset of anticancer and antimicrobial peptides. 
Amino acid modifications were serially introduced to the peptide in order to 
maximize the prediction score. We chose only the modifications that occurred outside 
of the HMM alignment region. We stopped serial modifications as soon as the 
prediction model returned a score high enough to differentiate the query as an 
anticancer peptide. 
D. BLASTp ALIGNMENTS 
Using our peptide as a query against two datasets, we ran a BLASTp search using 
default parameters, except for the threshold cutoff of 1000, since the sequence is 
short. One dataset was downloaded from the APD2 web server containing all the 
experimentally validated antimicrobial/ anticancer peptides [15]; the second 
BLASTp search was against the NCBI database across Homo sapiens using all 
default parameters in order to test for sequence similarity with human proteins. 
E. 3D MODELLING 
In order to proceed with the 3D modelling for our peptide, we ran our peptide 
through I-TASSER, a web server for protein secondary structure prediction [22]. We 
submitted the query peptide sequence as a FASTA file. Finally, we downloaded I-
TASSER output files for modelling and analysis. 
We used the modelling and visualization software Chimera, developed by UCSF 
in order to produce all modelling and visualization figures and numbers [23]. The 
.pdb files from the protein sequence analysis and for the functional domains of the 
two most similar proteins predicted by I-TASSER were fed into Chimera and we 
conducted a series of alignments. We first superimposed all of the sequences using 
default parameters in the MatchMaker tool within Chimera. We then conducted the 
structural alignments in Chimera. 
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F. LIGAND AND BINDING SITE PREDICTION 
We conducted ligand and binding site prediction using the web server COACH 
for ligand prediction [24]. This web server predicts the possible ligands for a query 
sequence and returns the most likely binding sites and binding site amino acids based 
on the BioLip database [25]. The .pdb output files were downloaded and we fed them 
into the Chimera software for protein-ligand visualization and analysis. 
G. GENE EXPRESSION ANALYSIS 
We used the R statistical programming software in order to investigate the 
expression patterns of Pax6 and Meis2 (the closest transcription factors to our 
peptides). We constructed several loops towards this end. We first started by calling 
on the cgdsr and RCurl libraries within R. We then used the RCurl library to log into 
The Cancer Genome Atlas (TCGA) link containing only the TCGA study data. 
Initially, we looked at Pax6 and Meis2 expression data in general across all TCGA 
studies. We constructed a loop that obtains the TCGA mRNA sequencing median z-
scores. The loop then computes the mean expression scores and deposits the results 
in a matrix. A box plot was generated from within R to present the results. 
Subsequently, we wanted to get a more detailed look at the expression data for 
Pax6 and Meis2 in each cancer study. We constructed another loop to build a matrix 
to hold the expression data for the gene of interest in each individual study. We called 
on second generation RNA sequencing median z-scores in this loop. We Only 
included the studies containing fully analyzed data. A bar plot was generated from 
within R to present the data. 
Finally, we were interested in studying the differential expression patterns of Pax6 
and Meis2 between normal and cancer cells. We obtained level 3 RNA sequencing 
data (normalized number of reads) for 15 cancer samples with their paired normal 
tissue from the TCGA data portal. We subsequently constructed a count matrix in R 
by combining all normal and cancer expression data with their genes into one matrix. 
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In order to examine differentially expressed genes, we used the EdgeR library. We 
followed the same workflow pipeline proposed by the Edger User’s Guide for 
comparing cancer versus matched normal RNA-sequencing data. 
2 )  L a b o r a t o r y  V a l i d a t i o n  
A. DRUG SYNTHESIS AND PREPARATION 
The peptide drug was synthesized by GL Biochem LTD, Shanghai, China and 
shipped as a lyophilized powder. The peptide was synthesized at 98% purity. We 
stored the lyophilized powder in the -20 freezer in a sealed vial away from light.  
We prepared stock solutions of our drug by dissolving the powder in deionized 
water at a concentration of 1 mg / ml. We stored the stock solutions in 1 ml Eppendorf 
tubes split into 0.5 ml aliquots. 
B. CELL CULTURE 
We used HepG2 (high passage number), HeLa cells, and 1BR- hTERT cells in 
this study. The HepG2 cells were previously purchased from Vacsera, Egypt; they 
are a hepatocellular carcinoma cell line derived from a hepatocellular carcinoma of a 
15-year-old Caucasian male [26]. HeLa cells are a permanent human 
adenocarcinoma cell line derived from a rare cervical adenocarcinoma of a 30-year-
old black female [27, 28].The 1BR-hTERT cell line is an immortalized human skin 
fibroblast cell line. Both the HeLa and 1BR-hTERT cells were kindly provided by 
Dr. Andreas Kakarougkas. 
We maintained the HepG2 cells in RPMI-1641 media (Lonza) completed with 
10% heat inactivated fetal bovine serum (FBS) and 5% Penicillin-Streptomycin. The 
HeLa cells were kept in DMEM (Lonza) completed with 10% heat inactivated FBS 
and 5% Penicillin-Streptomycin. The 1BR-hTERT cells were kept in the same 
conditions as the HeLa cells. We incubated the cell culture flasks at 37 degrees 
Celsius with 5% CO2. We observed the cells under the Olympus 1X70 microscope 
for morphology and cell death. 
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C. CELL COUNT 
In order to count cells for seeding, we used trypan blue staining. 20 µl of cells 
were mixed thoroughly with 20 µl of trypan blue dye and the cells were counted 
using a hemocytometer slide over 4 chambers. We calculated the number of cells 
using the following formula: 𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐𝑒𝑙𝑙𝑠	𝑝𝑒𝑟	𝑚𝑖𝑙𝑙𝑖𝑙𝑖𝑡𝑒𝑟 =𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓		𝑐𝑒𝑙𝑙𝑠	𝑐𝑜𝑢𝑛𝑡𝑒𝑑	𝑥	 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛	𝑓𝑎𝑐𝑡𝑜𝑟	 ÷𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐ℎ𝑎𝑚𝑏𝑒𝑟𝑠	𝑢𝑠𝑒𝑑 	𝑥	10,000  
D. CELL CYTOTOXICITY ASSAY 
We used the MTT assay in order to determine cell cytotoxicity after exposure to 
the test condition. The MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
bromide) reagent is a yellow tetrazolium compound which reacts with the 
mitochondrial dehydrogenase enzymes of viable cells. The reaction of the MTT 
reagent with the dehydrogenase enzymes forms purple formazan crystals[29]. In 
order to detect cell viability, as a measure of the cell cytotoxicity, after exposure to 
the test conditions, we seeded HepG2 or HeLa cells in a 96- well plate (Corning, 
USA) at a density of 1 x 104 cells in 100 µl of fresh complete media. After 24 hours 
from seeding, we discarded the old media and added the peptide drug at 
concentrations of 512, 256, 128, 64, 32, and 16 µg / ml diluted in fresh media by 
serial dilutions. 24 hours following addition of the drug, we replaced the old media 
with fresh media containing 0.5 mg/ml MTT (5mg/ml stock) (Serva, Germany) to 
each well. We incubated the plate for 3 hours. We then discarded all the media and 
added 100 µl of DMSO (Sigma-Aldrich, USA) to each well in order to dissolve the 
formazan crystals. We incubated the plate at room temperature, wrapped in 
Aluminum foil for 15 minutes. We measured absorbance at 490 nm using the BMG 
Labtech Spectrostar Nano plate reader. 
We calculated cell viability by subtracting the blank absorbance reading from all 
other wells. We then divided the sample absorbance reading by the control 
absorbance reading then multiplied by 100. 
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For all experiments, we used several control conditions as follows: blank (media 
with no cells), cells with complete media only, and cells with media and the solvent 
used to prepare the drugs employed in the study. The solvent control was prepared 
only for the highest drug concentration (i.e. as if preparing the 512 µg/ml but with no 
drug). We subsequently converted mass volumes to molar volumes. 
E. CELL DEATH ASSAY 
We used the AlexaFlour 488 AnnexinV/ Dead Cell kit from ThermoFischer 
Scientific in order to evaluate the mode of cell death in the treated cells. During the 
highly regulated and programmed mode of cell death (apoptosis), the apoptotic cells 
present phosphatidyl serine (PS) on the outer leaflet of their plasma membranes. 
Annexin V, a human anticoagulant and phospholipid binding protein can readily bind 
PS presented on the outside of the apoptotic cells. When conjugated with a 
fluorophore, Annexin V can emit green light when excited with ultraviolet light. 
Moreover, propidium iodide (PI) is a fluorophore that can tightly bind nucleic acids. 
Live and apoptotic cells are impermeable to PI. PI, however, can permeate into dead 
cells and bind their nucleic acids. When excited with ultraviolet light, PI emits red 
light [30, 31]. 
We plated 0.3x106 HepG2 cells per well in a 6- well plate. We plated wells for 
untreated control and drug treated (15.2 µM) conditions in duplicate. After 24 hours 
we discarded the spent media and added the peptide drug to the treatment wells. After 
another 24 hours we collected the media containing the floating cells and deposited 
them in a 15ml falcon tube. We subsequently trypsinised the adherent cells and 
combined those cells with the dead cells in the same falcon tube. We then pelleted 
the cells by centrifugation for 5 minutes at 500 RCF 4 degrees Celsius. The 
supernatant was discarded and the cells were re-suspended in 1 ml fresh media. 20 µl 
of the cell suspension was used for counting. We then collected the appropriate 
amount of cell suspension in order to obtain 50,000 cells. We pelleted this suspension 
and washed with 100 µl PBS. Again, we pelleted the cells and re-suspended in 1x 
Annexin binding buffer. We added 2 µl of the Annexin V reagent to the cell 
suspension in addition to 1 µl of PI. We incubated the cells suspension in the dark for 
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15 minutes at room temperature. 25 µl of the resulting cell suspension was then 
transferred to a glass slide and a cover slip was carefully placed over the droplet. We 
visualized the cells under the microscope using the appropriate FITC filters. 
3 )  S t a t i s t i c a l  A n a l y s i s  
In order to calculate mean viability readings and standard deviation, we used the 
raw un-blanked absorbance readings as input to the R statistical analysis software. 
We trimmed the unused wells out of the absorbance readings table and blanked all 
the absorbance readings. We also calculated the mean viability for each treatment. 
We used the GraphPad Prism software to calculate the half maximal drug response 
values (EC50) and to draw the dose response curves. We entered the raw viability data 
for each set of replicates in each experimental condition along with the different 
concentrations used. After the drug concentrations were log transformed and the data 
normalized, we calculated the EC50 values. Furthermore, we tested the data for 
normality and subsequently carried out either parametric or non-parametric two- way 
ANOVA with multiple comparisons in order to obtain significance values for the 
viabilities across the different drug concentrations. 
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 RESULTS 
1 )  A  p r e d i c t e d  3 7 - r e s i d u e  a n t i c a n c e r  
p e p t i d e  
We screened the AUC Metagenomic library across translated sequences for 
potential anticancer peptides. We obtained a list of 59 potential anticancer peptides, 
in terms of anticancer versus antimicrobial and anticancer versus random peptide 
scoring performance. While applying the filtering methods described, any anionic 
peptides were disregarded and any peptides with a size larger than 50 amino acids 
were also disregarded (since most anticancer peptides are cationic and fall within the 
size range between 5 – 50 amino acids, roughly [5, 6]); two candidate peptides 
remained. Both peptides contained HMM alignment profiles indicating presence of a 
homeodomain (PF00046.). One peptide was 30 residues long while the other was 37. 
We chose the 37 residue peptide, even though the shorter peptide was more cationic 
since the homeodomain HMM occurred on residue 0 to 30 on the shorter peptide; 
this would present a problem when optimizing the peptide since any mutations 
introduced would likely influence the HMM alignment. This 37-mer peptide came 
from the Atlantis II Deep brine pool sub-seafloor sediment section 6; the original 
sequence of which can be found on the NCBI Short Sequence Archive (SRA) under 
the name of the American University in Cairo along with the entire American 
University in Cairo Red Sea Metagenomic Library. The original peptide sequence 
was TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVMLTSI (Table 2). The 
modified and optimized peptide sequence contains 3 Cysteins at positions 33, 34, and 
36 in place of the original amino acids. The optimization of the original peptide 
resulted in an increase in the model performance score; furthermore, the 
hydropathicity of the peptide increased (Table 3). 
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Table 2: Anticacancer Peptide Drug Information. 
Nature of Data Data  
Dataset ATII-6Sediments_qc-prot.acp 
SVM Score 3 
Peptide length 37 
HMM id Homeobox 
HMM accession PF00046.24 
HMM start 1 
HMM end 31 
ACP/AMP model prediction (Tyagi, 
Atul, et al. 2013) 0.74 
ACP/NON-ACP model prediction 
(Tyagi, Atul, et al. 2013) -0.98 
Hydrophobicity -0.18 
Hydropathicity -0.39 
Hydrophilicity 0 
Charge 4 
Molecular weight 4334.71 
Table 3: The new chemical properties of the modified anticancer peptide 
 
ACP/NON
-ACP 
model 
prediction 
(Tyagi, 
Atul, et al. 
2013) 
Hydropho
bicity 
Hydropath
icity 
Hydrophili
city Charge 
Original -0.98 -0.18 -0.39 0 4 
Modified 0.28 -0.2 -0.34 -0.01 4 
2 )  T h e  p r e d i c t e d  a n t i c a n c e r  p e p t i d e  i s  a  
h o m e o d o m a i n  p r o t e i n  t h a t  a l i g n s  w i t h  a n  
A r t h r o p o d  d e f e n s i n  
We ran the chosen peptide sequence through a BLASTp search against two 
datasets; one contained a list of experimentally validated anticancer/random peptides 
from the AntiCP web server; the second dataset contained a list of experimentally 
validated anticancer peptides from the APD2 peptide library. For the AntiCP dataset, 
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our peptide aligned best with an anticancer/ anti-Gram+ peptide from Drosophila 
virilis [32] (coverage= 24%, identity = 56%, E-value = 7.1) . The results for the 
second alignment yielded an alignment with an Arthropod defensin from Stomoxys 
calcitrans (the stable fly) [33] (coverage = 72%, identity = 33%, E-value = 9). We 
submitted this peptide to the AntiCP server anticancer peptide prediction tool and it 
predicted that this peptide is also an anticancer peptide; We also ran this sequence as 
a query on the PFAM web tool and it confirmed that this sequence is that of an 
arthropod defensin. 
We ran our peptide through a third BLASTp search. This instance, however, we 
ran our peptide against the NCBI non-redundant (nr) database and included only 
Homo sapiens in the search. The best alignment was with the human homeobox gene 
Six2 (E-value = 0.012) (Figure 2).  
 
3 )  T h e  p e p t i d e  c o n t a i n s  a  h e l i x  t u r n  h e l i x  
s t r u c t u r e  a n d  i s  s t r u c t u r a l l y  s i m i l a r  t o  
P a x 6  
In preparation for modeling and visualization of the predicted anticancer peptide, 
we submitted the peptide sequence to I-TASSER, a web server for protein secondary 
structure prediction. I-TASSER results indicated that our peptide consisted, 
structurally, of two helices separated by a coiled region (C-score = -0.17); the two 
helices lay  roughly perpendicular (about 79 degrees) to one another, in accordance 
to the consensus geometry of the homeodomain[34] (Figure 3). The protein 
Figure 2: Summary of the best alignment returned by BLASTp against our 
peptide. 
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structurally closest to our peptide is the homeodomain of the human paired box 
protein, Pax6 (TM-score = 0.815, RMSD = 1.39, coverage = 1.000) (Figure 4).  
  
Figure 3: 3D rendering of our peptide drug with two alpha helices forming an 
angle of about 79 degrees. 
Figure 4: Top 10 structurally closest proteins to our peptide as predicted by 
TM-align tool within I-TASSER. We choose the second best structure 
(structure arranged in descending order) since the first structure does not cover 
the entire length of the sequence. 
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As a confirmatory step, we obtained the homeodomain structure of Meis2 (one of 
the proteins used by I-TASSER as a template to build our peptide structure, also a 
human homeodomain protein) (Figure 5) protein and Pax6 and subsequently fed them 
into Chimera with our peptide and we carried out two alignments: our peptide against 
Pax6 and our peptide against Meis2. Our peptide aligned, in terms of sequence 
(within 5 angstroms across all residues), with Meis2 at 42.42% identity across non-
gap stretches. On the other hand, Pax6 aligned with our peptide at only 13.5% identity 
across non-gap stretches.  
The Pax6 homeodomain structure, however, was the closest to our peptide with a 
plane angle between the planes of the C-terminal recognition helix and the two short 
N-terminal helices of 78.3 degrees (figure 6b), as opposed to 79 degrees in our 
peptide (figure 6a); Meis2 plane angles, however, were less congruent with our 
peptide, at 62.3 degrees (Figure 6c). 
Figure 5: Top 10 templates used by I-TASSER to build the structure of our 
peptide. We chose the second best template (Meis2 – results are arranged in 
descending rank order) since it is a human protein, as opposed to PBX (the best 
alignment) since it is a mouse protein. 
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4 )  O u r  p e p t i d e  b i n d s  D N A  o v e r  t h e  s a m e  
s e q u e n c e s  a s  t h e  a n t e n n a p e d i a  
h o m e o d o m a i n  
We wanted to find out the potential ligands for our peptide; therefore, we 
submitted the structure file of our peptide (output by I-TASSER), to the ligand 
prediction software, COACH. The most significant result was the output from the 
COFACTOR tool within COACH. Our peptide was shown to bind nucleic acids, with 
residues 5, 20, 24, 27, 28, 31 forming the binding site (C-score = 0.1). The closest 
protein-nucleic acid set used by COACH prediction as a template for ligand 
predication was from the Antennapedia homeodomain structure bound to DNA (PDB 
9antA, TM-score = 0.767, RMSD = 0.81, coverage = 0.919). Using this model, we 
were able to infer the DNA sequence to which our peptide would most likely interact: 
5’-AGAAAGCCATTAGAG-3’ (Figure 7). This sequence contains the 
homeodomain- specific recognition sequence 5’-ATTA-3’.
Figure 6: Plane angles formed between the recognition helices and N-terminal 
helices of: A- our peptide, B- Pax6, and C- Meis2. The planes themselves simply 
indicate the plane formed by each helix for ease of viewing. 
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Figure 7: 3D representation of our peptide (turqoise) aligned with 
the Antennapedia homeodomain. The C-terminal recognition helix 
is aligned with the major groove of the DNA molecule in the same 
orientation as its template indicating sequence- specific interaction 
potential. 
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5 )  P a x 6  a n d M e i s 2  e x p r e s s i o n  p a t t e r n s  
a c r o s s  s e v e r a l  c a n c e r s  o v e r  T C G A  
s t u d i e s  
Upon analyzing the expression data for Pax6 and Meis2, which we compiled from 
TCGA, we observed that Pax6, on average, displays weak underexpression patterns 
in the TCGA studies. We also observed that Meis2 shows a much more pronounced 
average underexpression across the TCGA studies, on average (Figure 8).  
When taking a closer look (Figure 9), we observed that Pax6 was overexpressed 
in breast and liver tissue, while being underexpressed in cervical tissue. Meis2, in 
contrast, was downregulated in breast and cervical tissue, while being upregulated in 
liver tissue. 
Figure 8: Average gene expression patterns for Pax6 and Meis2.  
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We were also interested in confirming the differential expression patterns of Pax6 
and Meis2 in Liver Hepatocellular Carcinoma, represented by the HepG2 cell line in 
our laboratory. 
 
Figure 9: Expression levels for Pax6 and Meis2 in select cancer types 
representing the cell lines most widely used in our laboratory. 
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We examined the data obtained and observed, as expected, that the normal 
samples were more homogeneous and tightly grouped than the tumor samples (Figure 
10). The cancer samples were clustered chiefly into 3 major groups; we tried 
searching in the patient data for a link between the clusters, however, we were not 
able to find a clear link (Table 4). 
  
Figure 10: Sample dispersion according to patterns of gene expression for 
all genes in each HCC sample. The axes represent the leading log of fold 
change. The samples for the cancer tissue red, blue, and orange circles) appeared 
more dispersed and heterogeneous indicating varying expression levels. The 
paired normal tissue samples (green circle) were tightly grouped and more 
homogenous, indicating consistent expression patterns. 
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Table 4: Hepatocellular Carcinoma Patient Information 
Cluster Sample 
Nr. Case Gender Age Stage 
Blue 1 TCGA-BD-A3EP Female 75 I 
Blue 2 TCGA-DD-A3A3 Male 45 I 
Orange 3 TCGA-DD-A3A4 Male 37 IIIa 
Orange 4 TCGA-DD-A3A5 Female 66 III 
Red 5 TCGA-DD-A3A6 Female 72 II 
Orange 6 TCGA-DD-A3A8 Male 75 II 
Blue 7 TCGA-EP-A3RK Male 73 IIIa 
Red 8 TCGA-FV-A3I0 Female 76 II 
Blue 9 TCGA-FV-A3I1 Female NA II 
Orange 10 TCGA-FV-A3R2 Male 75 I 
Orange 11 TCGA-G3-A3CH Male 53 IIIa 
We observed that Pax6 and Meis2 were, indeed, expressed in liver hepatocellular 
carcinoma; however, not differentially expressed (P<0.05) between normal and 
tumor samples (Table 5). 
 
Genes log Fold Change PValue 
PAX6 0.158089913 0.716262029 
MEIS2 0.742735053 0.171200501 
Table 5: Differential Gene Expression Data for Pax6 and Meis2. 
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6 )  D o s e -  d e p e n d e n t  c y t o t o x i c i t y  u p o n  
t r e a t m e n t  o f  H e p G 2  c e l l s .  
We treated the HepG2 cells with our peptide at concentrations ranging from 512 
to 3.7 µM. We noticed dose- dependent cytotoxicity with increasing drug dosage 
(Figure 11).  At the highest concentration, 121.5 µM, we obtained around 34% 
viability.  The viability gradually increased to about 73% for the lowest drug 
concentration of 3.8 µM. The concentrations which displayed statistically significant 
results were 121.5 – 3.8 µM (P < 0.001). The EC50 for our peptide drug was calculated 
to be about 8.6 µM. 
Figure 11:Cytotoxicity drug response curve of HepG2 cells treated with our 
peptide drug. Significance values are indicated relative to the control. 
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Upon examination of the drug treated HepG2 cells under the microscope, we 
observed a vast morphological difference between control cells, and cells treated with 
our peptide (Figure 12). Peptide-treated cells, however, looked enlarged, the cell 
Figure 12: Morphological changes in HepG2 cells induced by our peptide 
drug. A- Control cells incubated with media only; B- Cells treated with 121.5 
µM of our peptide drug. The peptide drug treated cells, at the highest 
concentration, appeared enlarged and had irregular shapes (rectangle) in 
addition to a few cells with vacuoles indicated by the circles. 
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surface looked rough, and the cells displayed multiple extensions. We also observed 
a few vacuoles in the cells of the highest concentration. The morphological changes 
gradually subsided with decreasing drug concentration. 
7 )  I r r e g u l a r  c y t o t o x i c i t y  r e s p o n s e  o f  H e L a  
c e l l s  t o  t r e a t m e n t  w i t h  t h e  p e p t i d e  d r u g  
In contrast to HepG2, Treatment of HeLa cells with our peptide (Figure 13) drug 
did not elicit the same pronounced dose- response. At the highest concentration 
(121.5 µM), our drug resulted in 73.5% viability; the lowest concentration (3.8 µM) 
resulted in 87% viability. None of the treatment concentrations yielded statistically 
significant differences in viability with a P- value below 0.001. 
Figure 13: Cytotoxicity drug-response curve of HeLa cells treated with our 
peptide drug. 
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Upon examination of the drug treated cells under the microscope, we were able to 
observe many vacuoles in the cells treated with the highest concentration (Figure 14). 
Figure 14: Microscopy for HeLa cells treated with our peptide drug. A- 
control cells only with growth media; B- Cells treated with our peptide drug at 
512 ug/ml. The treated cells were relatively morphologically different and 
displayed many vacuoles (red circles). 
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Some cells displayed irregular morphology as compared to the untreated control. 
8 )  C y t o t o x i c i t y  r e s p o n s e  o f  t h e  1 B R - h T E R T  
c e l l s  i n c u b a t e d  w i t h  t h e  p e p t i d e  d r u g  
We observed a dose- dependent reduction in the viability of the 1BR-hTERT cells 
upon treatment with increasing concentration of our drug (Figure 15). The highest 
concentration yielded a viability of about 52%; the viability gradually increased to 
approximately 88% at 15.2 µM, where the viability plateaued for the remaining 
concentrations. The EC50 for the 1BR-hTERT cells was calculated to be 
approximately 20.1 µM. The concentration of the drug used on the 1BR-hTERT cells 
that was closest to the EC50 on HepG2 (7.6 µM) resulted in a non-significant drop in 
viability as compared to the untreated control (that is, our peptide drug is not toxic to 
normal cells at its HepG2 EC50)). 
Upon examination of the cells under the microscope, we were able to observe a 
slight morphological difference between the treated and untreated cells (Figure 16). 
The treated cells at the highest concentration appeared irregular and shrunken. We 
Figure 15: Cytotoxicity drug-response curve for 1BR-hTERT cells treated 
with our peptide drug. All significance values were calculated relative to the 
control. only the concentrations from 121.5 to 15.2 µM displayed significant 
differences. 
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observed that this morphology subsided gradually down to the 15.2 µM concentration 
where the cells were only slightly smaller than the untreated cells. 
Figure 16: Microscopy images of 1BR-hTERT cells treated with our peptide 
drug. A- control cells with growth media only. B- cells treated with 121.5 µM 
of drug. The cells treated with the highest concentration appeared to be smaller 
and irregular in comparison to the control; those effects gradually subsided with 
decreasing concentration. 
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9 )  I n c r e a s e  i n  a p o p t o t i c  a c t i v i t y  u p o n  
t r e a t m e n t  o f  H e p G 2  c e l l s  w i t h  t h e  
p e p t i d e  d r u g  
We qualitatively examined the mode of death for the HepG2 cells treated with the 
peptide drug using ThermoFischer’s AlexaFlour488 Annexin V/ Dead Cell assay. 
We observed a marked increase in apoptotic activity between treated and untreated 
cells (Figure 17). Furthermore, we observed that the apoptotic cells from the drug 
treated sample could be divided into two major groups: early and late apoptotic cells. 
The early apoptotic cells appeared as bright green with faint or no red signal from PI 
staining. The majority of the cells, however, were late apoptotic; these cells presented 
as green-stained rings with a strong red signal in the center. We counted 1 early 
apoptotic cell in the control from about 45 cells in bright field. In contrast, we counted 
12 late apoptotic cells and 15 early apoptotic cells (with a total of 27 cells in bright 
field) for the drug treated condition, in the microscope viewing field. 
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Figure 17: Annexin V/ PI staining of HepG2 cells treated with our anticancer 
peptide drug. Left column is the control, Right column is the drug treated cells. A, 
B- bright field; C, D- Annexin staining (the arrows point to cells of late apoptosis 
while the circles indicate early apoptotic cells; E, F- PI staining; G, H- combined 
channels. These images indicate an increase in apoptotic activity in the drug treated 
cells as opposed to the control. 
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DISCUSSION 
Peptide based therapeutics are currently gaining attention as a replacement, or at 
least, a complement to small molecule therapeutics [4, 14, 35]. Large peptide drugs, 
or biologics, circumvent the off target toxicity problem of small molecule drugs and 
also offer much stronger action; that is, since biologics are more specific and on-
target, a much lower dose is needed to achieve the same effect. Biologics, however, 
are expensive and tedious to produce. Small peptide drugs fall within the size gap 
between small molecule drugs and biologics (0.5 to 5 kDa); they combine the small 
size of small molecule drugs, and also the potency and specificity of biologics, while 
also being relatively inexpensive and relatively less tedious to produce[4-6]. 
Small peptides with anticancer activity are cationic, amphiphilic, peptides 
containing 5 to 50 amino acid residues. The cationic nature of those peptides confer 
their specificity towards the relatively anionic cancer cells, in contrast to small 
molecule chemotherapeutics while amphiphilicity aids in the plasma membrane 
permeation [5]. 
We were able to develop a workflow for detecting potential anticancer peptide 
sequences from the AUC Red Sea Metagenomic library using several support vector 
machines (SVM’s). Our SVM pipeline was able to identify a list of possible 
anticancer peptides from the AUC database. We filtered the resultant list of potential 
anticancer peptides for the most promising candidate. Furthermore, we optimized our 
peptide sequence in order to improve its performance in the SVM model. We believe 
that none of the peptides were initially recognized as anticancer in our model because 
more variation between anticancer and random peptide sequences was needed for the 
model to recognize the peptide as being anticancer (i.e. a larger sample size with more 
diverse sequences). The first SVM model (anticancer versus antimicrobial) was able 
to identify the anticancer peptides right away since we were comparing two different 
classes of small peptides. That is, comparing two different classes of proteins is easier 
in terms of SVM models as opposed to comparing a peptide to all other peptides. 
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We subsequently set out to gather some information about our peptide. We 
conducted a few BLASTp alignments on NCBI. The most significant searches 
suggested that the peptide aligns with an arthropod defensin and a human 
homeodomain protein, Meis2. These results suggest that our peptide may also 
possess some antimicrobial properties. Furthermore, the BLASTp results indicated 
that the peptide might potentially have transcriptional regulatory activity within the 
tumor cell; these results were confirmed by the HMM alignment which also indicated 
that the peptide is, in fact, a DNA binding homeodomain peptide. 
Secondary peptide structure prediction using I-TASSER combined with 
visualization and modelling using Chimera confirmed the presence of the DNA-
binding region of the homeodomain structure. The peptide contains two alpha helices 
separated by a coiled region. The size-asymmetric helices lay at an almost 
perpendicular angle to one another; a feature typical to homeodomain proteins[34]. 
Our peptide, however, lacks a third N-terminal short helix; put together, we 
concluded that our peptide contains only the C-terminal DNA binding portion of the 
homeodomain. 
Ligand prediction and modelling using COACH and Chimera confirmed the DNA 
binding activity of our peptide. We observed that the longer C-terminal helix does 
the actual peptide-DNA interaction. The closest template model used for ligand 
prediction by COACH was that of an Antennapedia homeodomain bound to DNA. 
When we observed that our peptide might possibly have a transcriptional regulatory 
mode of action we were concerned that it may not be able to localize inside the 
nucleus where it exerts its effect. The observation, however, that our peptide aligns 
with the antennapedia homeodomain sequence was reassuring since some research 
indicates that portion of the antennapedia homeodomain can be used as a nuclear 
localization signal in order to direct cell-penetrating peptides into the nucleus[36, 37]. 
In addition, we observed that our peptide is able to bind to DNA at the same sequence 
as the Antennapedia homeodomain. 
Based on the computational results, we initially hypothesized that our peptide will 
probably either competitively bind to the Pax6 or Meis2 target promoter sequences 
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and inhibit their effect or it will replace the action of inactive or mutated Pax6 or 
Meis2. However, since our peptide was able to elicit dose-dependent cytotoxicity in 
HepG2 cells and induce morphological changes in HeLa cells (two cancers with 
opposing expression patterns of Pax6 and Meis2), we refuted this scenario. We 
currently hypothesize that our peptide drug may be acting through one of the 
membranolytic modes of action; namely, the mitochondrial mediated apoptosis 
pathway. In order to confirm this hypothesis, it would be advisable to investigate the 
levels of active caspase 9 and 3 and oligomerized Apaf-1 since they are indicative of 
the mitochondrial mediated apoptotic pathway [5]. 
We also observed that the solvent in the 1BR-hTERT experiment did result in a 
significant drop in cell viability (P<0.001). We attribute this discrepancy to their 
being less growth medium available for the cells at the highest concentration (since 
the solvent control was prepared at the highest concentration) where the solution was 
about 50% deionized water and 50% media. This effect subsided once the drug 
concentration (and subsequently the amount of deionized water) decreased. There 
was, however, some degree of cell death that can be attributed to the drug since there 
was a significant difference (P<0.001) in viability between the highest concentration 
(121.5 µM) and the solvent control. This solvent “shadow” effect may be 
circumvented by preparing a more concentrated stock solution; for example, 2 mg/ml 
instead of 1 mg/ml. As for the HepG2 cells, we did not observe a significant 
difference (P<0.001) in viability between the untreated control and the solvent 
control, while there was a significant difference (P<0.001) between the highest 
concentration (121.5 µM) and the solvent control. 
Even though the results for HeLa treatment with our peptide drug did not yield 
any reliable dose response curve, we were in fact able to observe morphological 
differences between treated and untreated cells. The cells treated with 121.5 µM 
displayed numerous large vacuoles indicative of cellular distress. It would be of 
importance to try more time points for the treatment and observe if increasing 
treatment duration would result in a dose response to the peptide drug treatment. 
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In this study, we were able to construct an SVM model in order to sift through the 
AUC Red Sea Metagenomic library and identify potential anticancer peptides. Out 
of a list of about 59 potential hits, we were able to isolate one peptide using 
cationicity, length, and model performance score as the main criteria. We were also 
able to optimize this peptide for better model performance. 3D modelling and 
sequence/ structure alignments provided insight into the potential action of the 
selected peptide. Even though we were not able to clearly propose a distinct 
mechanism of action for our peptide, we were able to observe a dose- dependent 
cytotoxicity upon treatment with our peptide. In addition, we observed that our 
peptide displayed less toxicity towards normal cells than cancer cells. The 
performance and selectivity of our peptide can be augmented by introducing more 
mutations into the amino acid sequence. More in-depth experimentation is needed, 
however, in order to outline a more pronounced hypothesis regarding the mechanism 
of action of our peptide drug. The activity of caspases 3 and 9 along with Apaf-1 need 
to be examined. Furthermore, investigation of the mitochondrial potential may prove 
beneficial in order to investigate whether the peptide drug is directly disrupting the 
mitochondria. Our peptide drug may also be tested in combination with 
chemotherapeutic agents in the hope that the additive effect of both agents would 
lower the required dosage of each and reach a point of very low toxicity to normal 
cells. Towards evaluating toxicity, further testing would be required in order to shed 
light on levels of hemolytic activity of our peptide drug. There still remains much 
research to be carried out in the field of cancer therapeutics. The need for more 
specific, more potent, and less toxic therapeutics is higher than ever due to the 
increasing global cancer burden. 
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